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doi:10.1016/j.jfma.2011.09.010This study investigated the use of bioelectrical impedance analysis (BIA) as a means of asses-
sing body composition in patients with Prader-Willi syndrome (PWS). Segmental, multifre-
quency BIA was performed on 30 patients with PWS (16 males and 14 females; mean age:
8.1  3.9 years; age range: 2.9e19.6 years) using eight tactile electrodes. No patient had
received growth hormone treatment prior to baseline measurements. Standard deviation
scores for height, weight, and body mass index were e0.96  1.29, 2.28  2.66, and
3.14  2.74, respectively. Percentages of body fat, total body water, and soft lean mass were
45.9  10.8%, 36.6  7.3%, and 49.9  9.9%, respectively. Body fat percentage was positively
correlated with the body mass index standard deviation score (rZ 0.665, p < 0.01). Follow-up
BIA was also performed on five patients who received growth hormone therapy (duration of
treatment: 1.5e4.6 years). All of these patients showed reductions in their body fat percent-
ages after treatment. BIA confirmed a significantly higher percentage of body fat in patients
with PWS compared with normal children. These findings and the follow-up data can be used
to develop quality care strategies for patients with PWS.
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after an overnight fast at least 8 hours and withinPrader-Willi syndrome (PWS) is a congenital disorder char-
acterized by neonatal hypotonia, a typical facial appear-
ance, hypogonadism, short stature, childhood-onset
obesity, hyperphagia, developmental delays, and behavior
problems. Approximately 70e75% of cases result from
deletion of the PWS-critical region on paternal chromosome
15q11-13, 25e28% result from maternal uniparental disomy
(UPD), and the remaining 2e5% result from a mutation or
deletion in the imprinting center or some another
imprinting defect. Obesity usually develops in patients with
PWS after the first year of life and often becomes severe if
growth hormone treatment is not administered.1e4 Bram-
billa et al5 reported that children and adolescents with PWS
have a peculiar body composition that is characterized by
increased adiposity and reduced lean mass, even when
compared with normal subjects with the same body mass
index (BMI) who are simply obese.
Dual-energy X-ray absorptiometry (DXA) and bioelectrical
impedance analysis (BIA) are both safe and easily accessible
methods for assessing body composition.6 Although DXA is
accurate and reproducible,5,7,8 it is complicated to perform
and too expensive for routine clinical use. BIA, on the other
hand, is a simple, inexpensive, and noninvasive method for
evaluating body composition. Information regarding the use
of this technique to evaluate patients with PWS is limited,9,10
even though it has been widely used by other health care
professionals, including health care researchers, fitness
trainers, and researchers at weight-control clinics.6,11e13 In
this study, we report our experience of using eight-polar,
segmental, multifrequency BIA to assess body composition in
PWS patients. Our goal was to provide a simple method that
couldbeusedasaclinical reference toevaluatePWSpatients.
Patients and methods
Selection of subjects
Thirty patients with PWS (16 boys and 14 girls; mean age:
8.1  3.9 years; age range: 2.9e19.6 years) were enrolled in
this study. This study was performed in three tertiary
medical centers in the greater metropolitan area of Taipei,
including Mackay Memorial Hospital, Taipei City Hospital,
and Taipei Tzu Chi Hospital. None of the enrolled patients
had received growth hormone treatment at the time of their
baseline measurements for this study. Five patients were
subsequently treated with growth hormones (0.1 IU/kg/day
administered subcutaneously); these patients are included
in the follow-up study. PWS was confirmed in all patients by
genetic analysis. Informed written consent was obtained
from a parent (for children under the age of 18 years) or
directly from patients over 18 years of age. The study was
approved by the ethics committee of Mackay Memorial
Hospital, Taipei, Taiwan.
Segmental multifrequency BIA
Body composition was assessed by segmental multi-
frequency BIA using eight tactile electrodes (InBody 3.0;Biospace, Seoul, Korea). Body composition was assessed
30 minutes of voiding the urinary bladder. The subject was
instructed to hold the electrodes in both hands and stand
on the footplate with bare feet. Physical exercise was not
allowed before the measurements were recorded. Analysis
was conducted at multiple frequencies, including 5 kHz,
50 kHz, 250 kHz, and 500 kHz. The segmental impedances
of the right arm, left arm, trunk, right leg, and left leg were
measured at each frequency. Each measurement took
about 2 minutes to complete, and the results were printed
directly from the InBody 3.0 device, which automatically
reported the values for fat mass, fat-free mass, and body
fat percentage that were calculated from the impedance
values using a previously described equation.14
Data analysis and statistics
Each patient’s gender, age, genotype pattern, Holm’s
score,1,15 height, weight, and BMI at the time of the study
were recorded. A standard deviation score (SDS) was
derived by subtracting the population mean from each
individual’s raw score and then dividing the difference by
the standard deviation of the population. SDSs for height,
weight, and BMI were calculated based on standard growth
tables for Taiwanese children.16 Results are expressed as
the mean  standard deviation unless otherwise indicated.
Two-tailed paired t-tests were used to determine statistical
significance. The effects of gender and genotype pattern on
Holm’s score; on SDSs for height, weight, and BMI; and on
each BIA value were analyzed using two-way analysis of
variance (ANOVA) using gender (males vs. females) and
genotype pattern (deletion vs. UPD) as the main effects.
The relationships between age and each BIA value and
between body fat percentage and the other BIA values were
tested using Pearson’s correlation, and significance was
tested using Fisher’s r-z transformations. SPSS version 11.5
(SPSS Inc., Chicago, IL, USA) was used to perform the
statistical analyses. Differences were considered statisti-
cally significant when p < 0.05. We also used published
values for body fat percentage, as measured by BIA in
normal Chinese children,11 as the standard against which to
compare the results obtained from the study patients.
Results
Genotype deletions were found in 25 patients (83%) and
maternal UPD was found in five patients (17%). The total
Holm’s score was 10.7  2.0 with a major criteria of
7.2  1.2. The SDS values of height, weight, and BMI were
e0.96  1.29, 2.28  2.66, and 3.14  2.74, respectively.
The body fat percentage, total body water, and soft lean
mass were 45.9  10.8%, 36.6  7.3%, and 49.9  9.9%,
respectively. The fat distribution, calculated using the
waistehip ratios of females and males, were 0.99  0.13
and 1.03  0.13, respectively. The body fat percentage was
positively correlated with the SDS for weight (r Z 0.581,
p < 0.01), SDS for BMI (r Z 0.665, p < 0.01) (Fig. 1) and
waist-hip ratio (r Z 0.431, p < 0.05) and negatively
correlated with the total body water percentage
(r Z 0.997, p < 0.001) and soft lean mass percentage
Figure 1 Body mass index (BMI) and standard deviation
scores (SDS) for body fat percentage of 30 patients with Prader-
Willi syndrome. Increased body fat percentage was associated
with an increased BMI SDS (r Z 0.665, p < 0.01).
Body composition in Prader-Willi syndrome 721(r Z 0.996, p < 0.001). There were no significant corre-
lations between gender or genotype pattern (deletion vs.
UPD) and the BIA results.
Baseline and follow-up BIA were performed on the five
patients who had received growth hormone therapy. These
patients received growth hormone therapy for periods
ranging from 1.5 to 4.6 years. In each case, treatment
resulted in reduced weight, BMI SDS, and body fat
percentage, as well as increased percentages of total body
water, soft lean mass, and fat-free mass. The percentages
of body fat, total body water, soft lean mass, and fat-free
mass were significantly different after receiving growth
hormone therapy (p < 0.05). However, due to the small
sample size, there were no statistically significant differ-
ences in weight or BMI SDSs (p > 0.05) (Table 1).Table 1 Baseline and follow-up bioelectrical impedance analysis
with growth hormone therapy for 1.5e4.6 years.
Gender Genotype
pattern
BIA Age
at BIA
(y)
GH therapy
duration (y)
Weight
SDS
BM
SDS
M Del Baseline 3.6 4.1 4.78 4.6
Follow-up 7.7 0.11 0.1
M Del Baseline 6.1 4.6 1.76 3.1
Follow-up 10.7 1.53 1.9
F Del Baseline 7.0 1.6 0.51 1.1
Follow-up 8.6 0.85 0.3
M UPD Baseline 7.6 1.5 0.57 0.5
Follow-up 9.1 0.63 0
M Del Baseline 10.6 1.5 0.75 0.3
Follow-up 12.1 1.12 0
p-value 0.360 0.1
BMI, body mass index; Del, deletion; FFM, fat-free mass; GH, growth h
TBW, total body water.Compared with the published reference values for
normal Chinese children,11 patients with PWS had a higher
percentage of body fat as determined by BIA. This was true
for both genders and all age groups (Fig. 2). Based on the
percentage of body fat, 93% (28/30) of our study subjects
were considered obese (> 95th percentile).
Discussion
Patients with PWS had significantly higher body fat
percentages, as measured by BIA, compared with those of
normal children.11 These patients were also shorter,
heavier, and had higher BMIs.16 BMI is the most widely used
anthropometric index of obesity, even though both local
and international reference standards are also avail-
able.16,17 However, BMI is just an index, not a measure-
ment, and it does not distinguish between increased mass
in the form of fat, bone, or lean tissue; thus, the use of BMI
may lead to the misclassification of some patients. As
explained above, DXA’s expense and complexity limit its
usefulness in routine clinical settings. It has, however, been
used in several investigations on untreated patients with
PWS.5,7,8 The percentages of body fat reported in those
studies ranged from 42.6 to 47.4% (Table 2), similar to the
results presented here calculated using BIA. Although we
did not perform a head-to-head study of these two
methods, our findings suggest that BIA is a less expensive
and readily available method that is reasonably accurate.
Similar comparisons have been made between the
segmental multifrequency bioelectrical impedance
analyzer used in this study (InBody 3.0) and DXA.12,13 The
values for fat mass, fat-free mass, and body fat percentage
derived using either technique correlate well with each
other. Additionally, our results are similar to those reported
by Davies et al,9 who used single-frequency BIA, and Shu
et al,10 who used the same InBody system as that used in
this study (Table 2). Shu et al10 also reported nine patients
who had been treated with growth hormone who were
subsequently reported to have a mean body fat percentageof five patients with Prader-Willi syndrome who were treated
I TBW
percentage
(%)
Soft lean
mass percentage
(%)
Body fat
percentage
(%)
FFM
percentage
(%)
7 27.8% 38.3% 57.4% 42.6%
2 54.5% 70.9% 23.1% 76.9%
4 37.6% 51.5% 44.0% 56.0%
7 38.7% 52.8% 43.7% 56.3%
3 30.3% 41.2% 54.0% 46.0%
7 45.5% 61.9% 32.5% 67.5%
1 30.7% 42.0% 53.4% 46.6%
.44 42.5% 57.5% 37.1% 62.9%
7 39.7% 54.2% 41.3% 58.7%
.57 41.6% 56.8% 38.7% 61.3%
17 0.013 0.011 0.012 0.012
ormone; UPD, uniparental disomy; SDS, standard deviation score;
Figure 2 Body fat percentages of 30 patients with Prader-
Willi syndrome (PWS) compared with the reference values for
normal Chinese children. (A) Boys; (B) girls.
722 H.-Y. Lin et al.of 34.0  9.8%. They did not, however, report the baseline
data for these nine patients. We, however, did compare
baseline and posttreatment values measured in the five
patients who received growth hormone. As expected, they
demonstrated reductions in their body fat percentages,Table 2 Comparison of published body fat percentages
using dual-energy X-ray absorptiometry or bioelectrical
impedance analysis for patients with Prader-Will syndrome
not treated with growth hormone therapy.
References Year Method n Age (y) Body fat (%)
Brambilla et al5 1997 DXA 27 6e22 47.4  7.2
Carrel et al8 1999 DXA 19 4e16 42.6  8.1
35 46.3  8.4
Ho¨ybye et al7 2003 DXA 19 17e37 45.2  4.0
Davies et al9 1992 BIA 14 2.9e16.0 42.0  10.7
Shu et al10 2007 BIA 11 8.6e23.3 44.3  9.0
Present study 2010 BIA 30 2.9e19.6 45.9  10.8
BIA, bioelectrical impedance analysis; DXA, dual-energy X-ray
absorptiometry.a result that was confirmed using repeated BIA
measurements.
We found no significant differences between gender or
genotype and the BIA results. To the best of our knowledge,
this is the first evidence that the genotype itself does not
significantly affect the body composition values that are
measured by BIA. However, this study consisted of a small
number of patients. It would be worthwhile to address this
question using a larger group of patients.
The waistehip ratio is the most widely used method for
evaluating abdominal fat distribution, with suggested cut-
off values of 0.80e0.90 for females and 0.94e1.00 for
males.18 In this study, 71% (10/14) of females and 50% (8/16)
of males had ratios above the cut-off values, suggesting
a high prevalence of abdominal obesity. Again, this finding is
expected in patients with PWS.
This study was limited in that it was unable to control.
We did not compare the BIA results to other methods that
can be used to assess body composition, nor did we simul-
taneously examine a control group of normal subjects using
the same technique. However, to the best of our knowl-
edge, this is the first study that used BIA to assess patients
with PWS, both before and after growth hormone therapy.
Previous studies have shown that growth hormone therapy
improves both the growth rate and body composition of
patients with PWS.19,20 Growth hormone therapy has been
endorsed by the National Health Insurance for the treat-
ment of PWS in Taiwan since May 2004. Since BIA is a rapid,
painless, and noninvasive method for evaluating body
composition,6,11e13 we urge the consideration of its use for
managing patients with PWS.Acknowledgments
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